Skip to content

Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections

Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06980571
Enrollment
100
Registered
2025-05-20
Start date
2006-06-30
Completion date
2008-12-31
Last updated
2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Disease

Keywords

liver resection, blood loss, resection technique, CUSA, radiofrequency ablation, health economics, benign and malignant liver disease

Brief summary

The purpose of this study is to determine whether a particular method of operating on the liver is superior to the gold standard commonest technique. CUSA (ultrasonic agitation) will be compared to the newer heat coagulation technique (radiofrequency ablation) and comparisons of blood loss, transfusion requirements, complication rates, hospital stay, effect on liver function, health economics and death rate will be made. The groups will be assessed for comparability in terms of underlying disease, resection type, underlying concurrent illnesses, sex, age, background liver disease. Standardisations of the rest of the operation will be carried out including anaesthetic technique and fluid requirements will be assessed by oesophageal Doppler. 100 patients will be recruited.

Interventions

DEVICEradiofrequency ablation

FDA approved intervention being compared with gold standard (most common intervention)

Sponsors

Barts & The London NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* any adult patient listed for liver resection giving informed consent

Exclusion criteria

* children, non-consent and diminished responsibility

Design outcomes

Primary

MeasureTime frame
Blood loss per cm squared of liver parenchyma cut throughoperation date until three months from discharge

Secondary

MeasureTime frameDescription
mortalityinpatient and thirty day mortalityincidence of post-operative complications measured over a thirty day period

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026